Mostrar el registro sencillo del ítem
dc.contributor.author | Cedena, Maria-Teresa | |
dc.contributor.author | Martin-Clavero, Estela | |
dc.contributor.author | Wong, Sandy | |
dc.contributor.author | Shah, Nina | |
dc.contributor.author | Bahri, Natasha | |
dc.contributor.author | Alonso, Rafael | |
dc.contributor.author | Barcenas, Carmen | |
dc.contributor.author | Valeri, Antonio | |
dc.contributor.author | Salazar Tabares, Johny | |
dc.contributor.author | Sanchez-Pina, Jose | |
dc.contributor.author | Cuellar, Clara | |
dc.contributor.author | Martin, Thomas | |
dc.contributor.author | Wolf, Jeffrey | |
dc.contributor.author | Lahuerta, Juan José | |
dc.contributor.author | Martinez-Lopez, Joaquin | |
dc.date.accessioned | 2020-11-16T08:53:28Z | |
dc.date.available | 2020-11-16T08:53:28Z | |
dc.date.issued | 2020-08-31 | |
dc.identifier.citation | PLoS One 2020 ;15(8):e0237155. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11344 | |
dc.description.abstract | Stringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited value in the era of minimal residual disease (MRD) testing. Here, we used 4-colour multiparametric flow cytometry (MFC) or next-generation sequencing (NGS) of immunoglobulin genes to analyse and compare the prognostic impact of sCR and MRD monitoring. We included 193 treated patients in two institutions achieving CR, for which both bone marrow aspirates and biopsies were available. We found that neither the serum free light chain ratio, clonality by immunohistochemistry (IHC) nor plasma cell bone marrow infiltration identified CR patients at distinct risk. Patients with sCR had slightly longer progression-free survival. Nevertheless, persistent clonal bone marrow disease was detectable using MFC or NGS and was associated with significantly inferior outcomes compared with MRD-negative cases. Our results confirm that sCR does not predict a different outcome and indicate that more sensitive techniques are able to identify patients with differing prognoses. We suggest that MRD categories should be implemented over sCR for the future classification of MM responses. | es_ES |
dc.description.sponsorship | This study was supported by grants of the Instituto de Salud Carlos III FEDER founds (Ministry of Economy and Competitivity, Madrid, Spain) FIS PI15/01484 and CRIS foundation grants 14/001 to JML. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Public Library of Science (PLOS) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | STEM-CELL TRANSPLANTATION | es_ES |
dc.subject | DEEP-SEQUENCING METHOD | es_ES |
dc.subject | CRITERIA | es_ES |
dc.subject | THERAPY | es_ES |
dc.subject | IMPACT | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Aged, 80 and over | es_ES |
dc.subject.mesh | Bone Marrow | es_ES |
dc.subject.mesh | Data Accuracy | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Flow Cytometry | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | High-Throughput Nucleotide Sequencing | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Immunoglobulin Light Chains | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Multiple Myeloma | es_ES |
dc.subject.mesh | Neoplasm, Residual | es_ES |
dc.subject.mesh | Plasma Cells | es_ES |
dc.subject.mesh | Prognosis | es_ES |
dc.subject.mesh | Progression-Free Survival | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.title | The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 32866200 | es_ES |
dc.format.volume | 15 | es_ES |
dc.format.number | 8 | es_ES |
dc.format.page | e0237155 | es_ES |
dc.identifier.doi | 10.1371/journal.pone.0237155 | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | CRIS contra el Cáncer | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1371/journal.pone.0237155 | es_ES |
dc.identifier.journal | PloS one | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/FIS PI15/01484 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/14/001 | es_ES |
dc.rights.accessRights | open access | es_ES |